Revenue Recognition - Disaggregation of Revenue (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended		12 Months Ended
	Sep. 30, 2021	Sep. 30, 2020	Sep. 30, 2021	Sep. 30, 2020	Dec. 31, 2020
Disaggregation of Revenue [Line Items]
Net Revenue	$ 15,988	$ 15,280	$ 46,599	$ 47,033	$ 60,000
Drug products
Disaggregation of Revenue [Line Items]
Net Revenue	279	284	835	776
Concentrate Products
Disaggregation of Revenue [Line Items]
Net Revenue	15,709	14,996	45,764	46,257
U.S.
Disaggregation of Revenue [Line Items]
Net Revenue	14,243	14,188	41,880	42,375
U.S. | Drug products
Disaggregation of Revenue [Line Items]
Net Revenue	217	228	656	609
U.S. | Concentrate Products
Disaggregation of Revenue [Line Items]
Net Revenue	14,026	13,960	41,224	41,766
Rest of World
Disaggregation of Revenue [Line Items]
Net Revenue	1,745	1,092	4,719	4,658
Rest of World | Drug products
Disaggregation of Revenue [Line Items]
Net Revenue	62	56	179	167
Rest of World | Concentrate Products
Disaggregation of Revenue [Line Items]
Net Revenue	1,683	1,036	4,540	4,491
Product Sales – Point-in-time | Drug product sales
Disaggregation of Revenue [Line Items]
Net Revenue	217	228	656	609
Product Sales – Point-in-time | Concentrate product sales
Disaggregation of Revenue [Line Items]
Net Revenue	15,224	14,506	44,308	44,786
Product Sales – Point-in-time | U.S. | Drug product sales
Disaggregation of Revenue [Line Items]
Net Revenue	217	228	656	609
Product Sales – Point-in-time | U.S. | Concentrate product sales
Disaggregation of Revenue [Line Items]
Net Revenue	13,541	13,470	39,768	40,295
Product Sales – Point-in-time | Rest of World | Drug product sales
Disaggregation of Revenue [Line Items]
Net Revenue	0	0	0	0
Product Sales – Point-in-time | Rest of World | Concentrate product sales
Disaggregation of Revenue [Line Items]
Net Revenue	1,683	1,036	4,540	4,491
License Fee – Over time | Drug license fee
Disaggregation of Revenue [Line Items]
Net Revenue	62	56	179	167
License Fee – Over time | Concentrate product license fee
Disaggregation of Revenue [Line Items]
Net Revenue	485	490	1,456	1,471
License Fee – Over time | U.S. | Drug license fee
Disaggregation of Revenue [Line Items]
Net Revenue	0	0	0	0
License Fee – Over time | U.S. | Concentrate product license fee
Disaggregation of Revenue [Line Items]
Net Revenue	485	490	1,456	1,471
License Fee – Over time | Rest of World | Drug license fee
Disaggregation of Revenue [Line Items]
Net Revenue	62	56	179	167
License Fee – Over time | Rest of World | Concentrate product license fee
Disaggregation of Revenue [Line Items]
Net Revenue	$ 0	$ 0	$ 0	$ 0